FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Dr Gaia Coppock examines approaches to guide colleagues and patients through the quickly changing landscape of IgA ...

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

Medically reviewed by David Ozeri, MD IgA nephropathy is a disease that can cause scarring in the kidneys.The kidney scarring from IgA nephropathy cannot be reversed once it occurs.While IgA ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Currently, several phase two and phase ...

New kidney treatment techniques achieved impressive results in some studies, with one method showing 71% kidney recovery ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Healio has compiled a list of its most-read nephrology ...

Diabetic nephropathy is a complication of diabetes that affects the kidneys. Hyperkalemia refers to high levels of potassium in the blood. Damage to the kidneys can result in hyperkalemia. Diabetic ...

Diabetic nephropathy is a slowly progressing condition that can be hard to detect. You may not notice any symptoms until your condition has progressed into later stages. Diabetic nephropathy happens ...